Last reviewed · How we verify
RBC
Red blood cell transfusion is used to increase the number of red blood cells in the body.
Red blood cell transfusion is used to increase the number of red blood cells in the body. Used for Anemia due to chronic kidney disease, Anemia due to chemotherapy, Anemia due to HIV infection.
At a glance
| Generic name | RBC |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | Blood product |
| Modality | Small molecule |
| Therapeutic area | Oncology, Hematology |
| Phase | FDA-approved |
Mechanism of action
Red blood cells carry oxygen throughout the body, and transfusions are used to treat conditions such as anemia or blood loss due to injury or surgery.
Approved indications
- Anemia due to chronic kidney disease
- Anemia due to chemotherapy
- Anemia due to HIV infection
Common side effects
- Allergic reaction
- Infection
- Iron overload
Key clinical trials
- Treatment of Hemochromatosis (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Photo-Acoustic and Ultrasonographic Mammoscope (PHASE2)
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (PHASE2)
- Mechanisms Accounting for Unexplained Anemia in the Elderly (PHASE1)
- A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia (PHASE2)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBC CI brief — competitive landscape report
- RBC updates RSS · CI watch RSS
- Asan Medical Center portfolio CI